Although many stakeholders have applauded the Centers for Medicare and Medicaid Services coverage determination regarding a new class of highly anticipated drugs that treat Alzheimer’s, some are concerned that the decision stopped short of addressing imaging related to the drugs’ use.

A fatal bleeding event in an Alzheimer’s clinical trial participant may have been linked with the investigational anti-amyloid agent lecanemab, a case report suggested.

ML Tool Detects Biomarker in Stroke Patients. RSNA/AAPM Symposium Focuses on Low-dose CT. Human Factors Impact Reporting of Safety Events. MRI-Based Technology Promising in Alzheimer’s. RSNA Online Series Targets Health Care Economics.